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Lung transplantation is an accepted therapy for patients with end-stage lung disease and offers a major
survival beneﬁt in selected patients. The most important indications are chronic obstructive pulmonary
disease and idiopathic pulmonary ﬁbrosis besides cystic ﬁbrosis and pulmonary arterial hypertension.
The incidence of lung cancer in patients after Ltx is 20e25 times higher than in the general population.
Diagnosis is often difﬁcult in IPF patients because of the diffuse lung abnormalities due to the underlying
ﬁbrosis. Moreover, the lung cancer may mimic a pulmonary infection. Symptoms are often aspeciﬁc,
diagnosis is difﬁcult, and prognosis is extremely poor. We describe three patients who were transplanted
for idiopathic pulmonary ﬁbrosis and who developed a primary lung cancer.
 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Lung transplantation (Ltx) is an accepted therapy for patients
with end-stage lung disease and offers a major survival beneﬁt in
selected patients. The most important indications are chronic
obstructive pulmonary disease (COPD) (29%) and idiopathic
pulmonary ﬁbrosis (IPF) (24%) besides cystic ﬁbrosis and
pulmonary arterial hypertension.1 The incidence of lung cancer is
4.1% in patients after Ltx, this is 20e25 times higher than in the
general population.2 Diagnosis is often difﬁcult in IPF patients
because of the diffuse lung abnormalities due to the underlying
ﬁbrosis. Moreover, the lung cancer may mimic a pulmonary
infection. We describe three patients who were transplanted for
idiopathic pulmonary ﬁbrosis and who developed a primary lung
cancer.been previously published in
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-NC-ND license.2. Cases
Patient A, a 48-year old male with IPF presented 7 years after
successful single Ltx with dyspnoea, weight loss and cough. At that
time he was renovating his house. A high resolution computed
tomography of the chest showed an increasing opacity in the native
lung replacing the ﬁbrotic lesions and noduli and ground glass
opacities in the transplant lung (Fig. 1). The differential diagnosis
consisted of fungus infection (exposure during renovating), rejection
and malignancy. No abnormalities were seen on bronchoscopy but
biopsies of the transplant lung showed a large cell carcinoma of the
lung with lymphangitis carcinomatosa. No extrathoracic metastases
were found on 18ﬂuorodeoxyglucose positron emission tomography
(18FDG-PET). Due to his poor performance (WHO 4) no oncological
treatment was started and he died shortly after. Patient B, a 58-year
old male with IPF, underwent a bilateral Ltx shortly after a single left
Ltx failed due to rejection. In the explanted right lung a squamous
cell carcinoma was found with mediastinal lymph metastases. No
extrathoracic metastases were found on 18FDG-PET. The lung cancer
was staged as pT2N2M0 and chemo-radiotherapy was started. 14
months later local progression appeared, shortly after initiation of
second line chemotherapy he died. Patient C, a 53-year old female
with IPF complained of left pretibial pain before transplantation. A
bone scintigraphy showed uptake in the left tibia, 18FDG-PET showed
uptake in both lungs and the left tibia. Uptake in the tibia was
suggestive for hypertrophic osteo-arthropathy and was interpreted
Fig. 1. Chest HRCT of patient A: increasing opacity in the left native lung replacing the
ﬁbrotic lesions and noduli and ground glass opacities in the transplant lung.
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of transplantation, however, she was diagnosed with an adenocar-
cinoma in both explanted lungs. New bone scintigraphy showed
multiple lesions suggestive for skeletal metastases. She died shortly
after. A summary is presented in Table 1.
3. Discussion
After Ltx the incidence of lung cancer is increased in contrast to
other solid organ transplant recipients.3,4 Lung cancer arises in the
majority of cases in the native lung but sometimes is found unex-
pectedly in the explanted lung. Risk factors are IPF itself, smoking,
older age, male gender, prolonged immunosuppression and single
Ltx.1
3.1. IPF
Causal mechanisms and frequency of lung cancer in IPF are
difﬁcult to determine. This is partly due to a yearlong lack of
uniform diagnostic criteria for IPF, making interpretation of the
literature difﬁcult. Uniform diagnostic criteria are now established
by the ATS/ERS in 2002 and better diagnosis is now expected.5 A
recent study found a rate ratio of 4.96 for developing lung cancer in
IPF patients compared to the general population; this wasTable 1
Summary patients AeC.
Patient A Pa
Age at diagnosis IPFa/Ltxb 46/48 years 53
Histologic conﬁrmation IPF yes, UIPc ye
Smoking status ex, 30 packyears ex
Treatment IPF
(all acetylcysteine/prednisone)
cyclophosfamide az
Singe or bilateral Ltx single (right) Af
bi
Histology explanted lung UIP, no malignancy lef
rig
Time Ltx to diagnosis of lung cancer 8 years, three months in
Stage lung cancer TxNxM1a (stage IV) T2
Treatment lung cancer none, performance too poor ra
pr
Time diagnosis lung cancer to death 3 months 1
a idiopathic pulmonary ﬁbrosis.
b lung transplantation
c usual interstitial pneumonia.independent of smoking status.6 Due to inﬂammation and repeat
injury induced by IPF, genetic errors may develop. Eventually this
can result in lung cancer.5
3.2. Smoking, age and gender
83e100% of transplanted patients who developed lung cancer
had a smoking history of at least 30 packyears.3,7 Patient A and B
had a smoking history of 30 and 26 packyears respectively, but
patient C was a life time non-smoker. Increasing age and male
predominance are also recognized risk factors.8,9
3.3. Immunosuppressive drug therapy
Long-term immunosuppression is thought to be carcinogenic
due to inhibition of immune-mediated tumour surveillance and
direct carcinogenic effects.8,9 In contrast to other solid organ
transplants, immunosuppression post Ltx is much more intensiﬁed
due to the common development of acute and chronic rejection.
This may be the explanation why other solid organ transplant
recipients do not have an increased risk of developing lung cancer.3
Aggressive tumour behaviour can also be attributed to the same
mechanism.3
3.4. Single versus bilateral Ltx
In a study of Dickson et al, 9/131 (6.9%) single lung transplanted
patients developed lung cancer in the native lung. 8 were trans-
planted for COPD and 1 for IPF, lung cancer developed after a mean
of 52 months following transplantation.8 Patient A also developed
a large cell carcinoma in the native lung but only after 99 months.
When a bilateral Ltx is performed, lung cancer is rarely accounted
although when it does, it mostly arises from the native lung
epithelium. The hazard ratio for developing lung cancer is 4.31 for
single Ltx versus bilateral Ltx after adjusting for age, native disease
and smoking.8 In 2% of patients lung cancer is unexpectedly found
in the explanted lung.1 This occurred in patient B and C although in
patient C, retrospectively, there was a suspicion of malignancy on
bone scintigraphy and 18FDG-PET. Reports of lung cancer arising
from the donor long are rare. This may be due to a younger donor
age and frequently a non-smoking status of the donor, although this
concept is rapidly changing as more and more extended criteria
donor lungs are now being used.1 Leuven and many other centers
worldwide have shifted to bilateral Ltx in more than 95% of IPF andtient B Patient C
/57 years 47/53 years
s, UIP yes, UIP
, 26 packyears never
athioprine azathioprine
ter rejection single (left) Ltx
lateral Ltx
bilateral
t: UIP
ht: squamous cell carcinoma
massive bilateral adenocarcinoma
with lymphangitis carcinomatosa
explanted lung in explanted lung
N2M0 (stage IIIA) T4N2M1b (stage IV)
dical chemo-radiotherapy,
ogression: chemotherapy
palliative radiotherapy symptomatic
skeletal metastases, performance too poor
for further therapy
year, 10 months 3 months
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primary lung cancer after bilateral Ltx being one of the reasons.
3.5. Symptoms and diagnosis
Only a minority of patients is asymptomatic, but symptoms are
usually aspeciﬁc7 or mimic an infection or rejection,3 as in patient
A. Chest CT scanning is more sensitive than chest x-ray to diagnose
lung cancer.4 18FDG-PET-scan may be false positive due to the
underlying ﬁbrosis or infection, as was wrongly suggested in
patient C. Mean time from Ltx to diagnosis of lung cancer is 40e52
months, in patient A this was much longer.3,7,8 Mean age at diag-
nosis is 59 years (range 52e64 years).3 Adenocarcinoma and
squamous cell carcinoma represent the most frequent pathological
types, followed by small cell carcinoma.7,9
3.6. Treatment and prognosis
Although disease is often diagnosed in an early stage, prognosis
remains extremely poor. Clinical course is frequently recurrent,
aggressive and fatal, as we encountered in all three patients. Due to
the underlying disease and immunosuppressive drugs, therapeutic
options are limited.7,8,10 Post-transplant survival rates of patients
with lung cancer at 1 and 2 years were 50% and 33% respectively.3
This in contrast with a 1 and 2 year survival of 90% and 85%
respectively in lung transplanted patients without lung cancer in
Leuven, Belgium.
4. Conclusions
Transplanted IPF patients are at increased risk for developing
primary lung cancer. Risk factors are IPF itself, smoking, older age,
male gender, immunosuppressive drug therapy and single Ltx.
Symptoms are often aspeciﬁc, diagnosis is difﬁcult, and prognosis is
extremely poor. These cases stress the importance of activelysearching for lung cancer before as well as after Ltx in patients
with IPF.
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